Dimeric Anthraquinone Rugulosin A Induces Apoptosis in Lung Adenocarcinoma and Targets PI3K/AKT/MAPK Pathways In Silico
ACS Omega · 31.03.2026 · 11 (12) · 18744-18759
DOI: 10.1021/acsomega.5c09585 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 19.03.2026. Verfasst von Joe Anthony H Manzano und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Graduate School, University of Santo Tomas, 1015 España, Manila, Philippines. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Philippine Council for Health Research and Development, Alexander von Humboldt-Stiftung.
Abstract (Originalsprache)
Cytotoxic anthraquinones are natural products that modulate apoptosis and oncogenic signaling pathways. In this study, three fungal anthraquinones citreorosein (1), skyrin (2), and rugulosin A (3) were investigated for cytotoxic, antiproliferative, and pro-apoptotic effects using in vitro assays. Rugulosin A (3) exhibited cytotoxic activity against six tumorigenic cell lines (IC50 = 0.138–1.475 μM). Although less potent than the nanomolar-range reference drug Epothilone B (IC50 < 0.1 μM), rugulosin A showed submicromolar-to-low micromolar efficacy with notable selectivity toward cancer cells, which is considered significant for an unoptimized natural product scaffold. Its antiproliferative activity against K562 cells (GI50 = 3.69 μM), benchmarked against Imatinib (GI50 = 0.373 μM), also falls within the active range of natural product leads. Caspase-Glo 3/7 and CellEvent assays demonstrated concentration-dependent apoptosis induction by 3 (p < 0.05), supported by Western blot detection of cleaved PARP-1 and caspase-3. Network pharmacology analysis identified ten potential gene targets enriched in oncogenic pathways, with AKT1, PIK3CA, and MAPK14 p38α emerging as putative key regulators. Molecular docking revealed strong binding energies (−10.1, −9.8, and −11.0 kcal/mol), along with a stable molecular dynamics simulations data. These findings highlight rugulosin A (3) as a promising anticancer lead that modulates major apoptosis signaling pathways.
Autor:innen und Institutionen
- The Graduate School, University of Santo Tomas, 1015 España, Manila, Philippines.
- Department of Biological Sciences, College of Science, University of Santo Tomas, 1015 España, Manila, Philippines.
- UST Laboratories for Vaccine Sciences, Molecular Biology, and Biotechnology, University of Santo Tomas, España Blvd., Manila 1015, Philippines.
- Research Center for the Natural and Applied Sciences, University of Santo Tomas, España Blvd., Manila 1015, Philippines.
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
- Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
ORCID-Profile: Elian Angelo M Abellanosa, Simone Brogi, Chia-Hung Yen, Kin Israel Notarte, Allan Patrick G Macabeo
Förderung
- Philippine Council for Health Research and Development
- Alexander von Humboldt-Stiftung
Zitieren
APA
Manzano, J. A. H., Abellanosa, E. A. M., Aguilar, J. P. P., Brogi, S., Yen, C. H., Notarte, K. I., Austriaco, N., & Macabeo, A. P. G. (2026). Dimeric Anthraquinone Rugulosin A Induces Apoptosis in Lung Adenocarcinoma and Targets PI3K/AKT/MAPK Pathways In Silico. ACS Omega, 11(12), 18744-18759. https://doi.org/10.1021/acsomega.5c09585
Vancouver
Manzano JAH, Abellanosa EAM, Aguilar JPP, Brogi S, Yen CH, Notarte KI, et al. Dimeric Anthraquinone Rugulosin A Induces Apoptosis in Lung Adenocarcinoma and Targets PI3K/AKT/MAPK Pathways In Silico. ACS Omega. 2026;11(12):18744-18759. doi:10.1021/acsomega.5c09585
BibTeX
@article{Manzano2026,
author = {Manzano, Joe Anthony H and Abellanosa, Elian Angelo M and Aguilar, Jose Paolo P and Brogi, Simone and Yen, Chia-Hung and Notarte, Kin Israel and Austriaco, Nicanor and Macabeo, Allan Patrick G},
title = {Dimeric Anthraquinone Rugulosin A Induces Apoptosis in Lung Adenocarcinoma and Targets PI3K/AKT/MAPK Pathways In Silico},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {12},
pages = {18744--18759},
doi = {10.1021/acsomega.5c09585}
}
EUVIMED